Cary Street Partners Investment Advisory LLC Intra Cellular Therapies, Inc. Transaction History

Cary Street Partners Investment Advisory LLC

$2.63 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 12, 2023	BUY	$43.8 - $56.99 $876 - $1,139	20 Added 1.27%	1,600 $86,000
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $69,630 - $86,031	1,580 New	1,580 $83,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$803 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.32M
Shares

$527 Million
0.01% of portfolio
Jpmorgan Chase & CO New York, NY

5.29M
Shares

$441 Million
0.03% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.85M
Shares

$321 Million
1.4% of portfolio
Avoro Capital Advisors LLC New York, NY

3.05M
Shares

$254 Million
3.36% of portfolio

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.87B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cary Street Partners Investment Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cary Street Partners Investment Advisory LLC with notifications on news.

Account